Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LY3526318 in Healthy Participants
NCT03977974Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3526318 in chronic pain (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration up to 32 Days. Started Jun 2019; status: terminated.
02
Drugs
LY3526318
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT03977974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03977974.